In ovarian cancer models, a Maraba-OVA (MRB-OVA) boost following peptide/adjuvant priming elicited potent tumor-infiltrating CD8+ T cell responses and delayed progression in an intraperitoneal ovarian tumor model [137]. Here, CD8A is linked to neoplasm.